Patents by Inventor Scott R. Presnell

Scott R. Presnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL-17A/F cross-reactive monoclonal antibodies and methods of using the same
    Patent number: 9708401
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: July 18, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brenda L. Stevens, Mark W. Rixon, Scott R. Presnell
  • Antibodies that bind both IL-17A and IL-17F
    Patent number: 9663572
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: May 30, 2017
    Assignee: ZYMOGENETICS INC.
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • IL-23 ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20170022272
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Application
    Filed: October 10, 2016
    Publication date: January 26, 2017
    Inventors: Brenda L STEVENS, Mark W. Rixon, Scott R. Presnell
  • USE OF AN IL-17/IL-23 BISPECIFIC ANTIBODY FOR TREATING INFLAMMATION
    Publication number: 20160376362
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and IL-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Application
    Filed: September 8, 2016
    Publication date: December 29, 2016
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • MONOCLONAL ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F
    Publication number: 20160311897
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
    Type: Application
    Filed: July 12, 2016
    Publication date: October 27, 2016
    Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
  • COMPOSITIONS AND METHODS FOR INHIBITING PDGFRbeta AND VEGF-A
    Publication number: 20160311909
    Abstract: Disclosed are antagonists of PDGF receptor ? (PDGFR?) and VEGF-A, including neutralizing anti-PDGFR? and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFR? and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFR? and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFR? and/or VEGF-A antagonist.
    Type: Application
    Filed: July 11, 2016
    Publication date: October 27, 2016
    Inventors: Pallavur V. SIVAKUMAR, Debra G. Gilberson, Marshall D. Snavely, George R. Mabry, Eugene C. Yi, Yue Yao, Scott R. Presnell
  • Polynucleotides encoding antagonists of IL-17A, IL-17F, and IL-23p19
    Patent number: 9464134
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: October 11, 2016
    Assignee: ZYMOGENETICS, INC.
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • Compositions and methods for inhibiting PDGFR? and VEGF-A
    Patent number: 9441034
    Abstract: Disclosed are antagonists of PDGF receptor ? (PDGFR?) and VEGF-A, including neutralizing anti-PDGFR? and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFR? and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFR? and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFR? and/or VEGF-A antagonist.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: September 13, 2016
    Assignee: ZYMOGENETICS, INC.
    Inventors: Pallavur V. Sivakumar, Debra G. Gilbertson, Marshall D. Snavely, George R. Mabry, Eugene C. Yi, Yue Yao, Scott R. Presnell
  • Methods of treating inflammatory diseases using antibodies that bind both IL-17A and IL-17F
    Patent number: 9416183
    Abstract: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: August 16, 2016
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
  • ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING SAME
    Publication number: 20160053008
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Application
    Filed: November 4, 2015
    Publication date: February 25, 2016
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • POLYNUCLEOTIDES ENCODING ANTAGONISTS OF IL-17A, IL-17F, AND IL-23P19
    Publication number: 20150197566
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Application
    Filed: February 20, 2015
    Publication date: July 16, 2015
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • POLYNUCLEOTIDES ENCODING ANTIBODIES
    Publication number: 20150099278
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Application
    Filed: December 19, 2014
    Publication date: April 9, 2015
    Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty
  • Antagonists of IL-17A, IL-17F, and IL-23P19
    Patent number: 8992922
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: March 31, 2015
    Assignee: ZymoGenetics, Inc.
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • BISPECIFIC ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20150086552
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Application
    Filed: May 21, 2013
    Publication date: March 26, 2015
    Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty, Milan Gao, Steven Sheriff, Noah Ditto, Nels B. Hamacher
  • Bispecific antibodies to IL-23 and IL-17A/F
    Patent number: 8945553
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: February 3, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty
  • METHODS OF TREATING INFLAMMATORY DISEASES USING ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F
    Publication number: 20150010553
    Abstract: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
    Type: Application
    Filed: September 23, 2014
    Publication date: January 8, 2015
    Inventors: STEPHEN R. JASPERS, SCOTT R. PRESNELL, MONICA J. HUBER
  • Polynucleotides encoding antibodies that bind both IL-17A and IL-17F
    Patent number: 8871467
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: October 28, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
  • ZCYTOR19 POLYNUCLEOTIDES, POLYPEPTIDES, ANTIBODIES AND METHODS OF USE
    Publication number: 20140248661
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class II cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor19, are located on chromosome 1p36.11, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Application
    Filed: April 2, 2014
    Publication date: September 4, 2014
    Applicant: ZymoGenetics Inc.
    Inventors: Scott R. Presnell, Francis J. Grant, Emily C. Costerison, Theodore E. Whitmore
  • Polynucleotides encoding antibodies to cytokine receptor zcytor17
    Patent number: 8648182
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: February 11, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Scott R. Presnell, Zeren Gao, Theodore E. Whitmore, Joseph L. Kuijper, Mark F. Maurer
  • Antibodies that bind both IL-17A and IL-17F
    Patent number: 8609099
    Abstract: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: December 17, 2013
    Assignee: Zymogenetics, Inc.
    Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica Huber